Cargando…
NLRP3, the inflammasome and COVID-19 infection
Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation and dysregulated cytokine release. These features are linked to the intense and rapid stimulation of the innate immune response. The NA...
Autores principales: | Yin, Maureen, Marrone, Laura, Peace, Christian G, O’Neill, Luke A J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382191/ https://www.ncbi.nlm.nih.gov/pubmed/36661317 http://dx.doi.org/10.1093/qjmed/hcad011 |
Ejemplares similares
-
The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
por: Coll, Rebecca C., et al.
Publicado: (2011) -
Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
por: Coll, Rebecca C., et al.
Publicado: (2013) -
Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
por: Coll, Rebecca C., et al.
Publicado: (2013) -
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
por: Hooftman, Alexander, et al.
Publicado: (2021) -
Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention
por: Zhang, Jiayu, et al.
Publicado: (2023)